Reuters logo
2 months ago
BRIEF-GSK has one hit, one miss with mepolizumab in Phase III COPD studies
May 10, 2017 / 3:44 PM / 2 months ago

BRIEF-GSK has one hit, one miss with mepolizumab in Phase III COPD studies

1 Min Read

May 10 (Reuters) - Glaxosmithkline

* Says one study misses, one hits statistical significance testing mepolizumab in patients with severe chronic obstructive pulmonary disease Source text for Eikon: Further company coverage: (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below